CORRESP 1 filename1.htm

 

ProQR Therapeutics N.V.

Zernikedreef 9

2333 CR Leiden

The Netherlands

31 88 166 7000

 

VIA EDGAR

 

November 15, 2018

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-4720

 

Re:              ProQR Therapeutics N.V.

Acceleration Request for Registration Statement on Form F-3

File No. 333-228251

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 19, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955.

 

Signature Page Follows

 

 

 

Sincerely,

 

 

 

PROQR THERAPEUTICS N.V.

 

 

 

/s/ Daniel de Boer

 

Daniel de Boer

 

Chief Executive Officer

 

cc:                 Smital Shah, ProQR Therapeutics N.V.

Paul van Dongen, ProQR Therapeutics N.V.

Mitchell S. Bloom, Goodwin Procter LLP

Danielle M. Lauzon, Goodwin Procter LLP